0001104659-20-087827.txt : 20200729 0001104659-20-087827.hdr.sgml : 20200729 20200729165726 ACCESSION NUMBER: 0001104659-20-087827 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200729 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 201057754 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2025879d1_8k.htm FORM 8-K
0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2020-07-29 2020-07-29 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-07-29 2020-07-29 0001551152 exch:XCHI us-gaap:CommonStockMember 2020-07-29 2020-07-29 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec2.125SeniorNotesDue2028Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec1.250SeniorNotesDue2031Member exch:XNYS 2020-07-29 2020-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 29, 2020

 

ABBVIE INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

 

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.01 Par Value   ABBV  

New York Stock Exchange

Chicago Stock Exchange

1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02.Results of Operations and Financial Condition.

 

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is certain unaudited financial information relating to the acquisition by AbbVie Inc. (“AbbVie”) of Allergan plc (“Allergan”), which closed on May 8, 2020. On page 1, AbbVie provides information with respect to its historical key product revenues for each of the quarters in the year ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March 31, 2020. On page 2, AbbVie provides information with respect to its comparable key product revenues for each of the quarters in the year ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March 31, 2020, which was prepared as if the acquisition of Allergan had closed on January 1, 2019.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit
No.

  

Description

     
99.1   Certain unaudited financial information relating to the acquisition by AbbVie Inc. of Allergan plc (furnished pursuant to Item 2.02).
     
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBVIE INC.
   
Date: July 29, 2020 By: /s/ Robert A. Michael
    Robert A. Michael
    Executive Vice President, Chief Financial Officer

 

 

Common Stock, $0.01 Par Value ABBV
EX-99.1 2 tm2025879d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

AbbVie Inc.

Key Product Revenues

Quarterly Trend Analysis

(Unaudited, in millions) 

  1Q19     2Q19     3Q19     4Q19     FY19     1Q20  
  U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.     Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total  
NET REVENUES $ 5,270   $ 2,558   $ 7,828     $ 5,964   $ 2,291   $ 8,255     $ 6,244   $ 2,235   $ 8,479     $ 6,429     $ 2,275   $ 8,704     $ 23,907   $ 9,359   $ 33,266     $ 6,158   $ 2,461   $ 8,619  
                                                                                     
Immunology 3,215   1,231   4,446     3,835   1,083   4,918     3,977   1,064   5,041     4,195     971   5,166     15,222   4,349   19,571     4,004   1,085   5,089  
Humira 3,215   1,231   4,446     3,793   1,077   4,870     3,887   1,049   4,936     3,969     948   4,917     14,864   4,305   19,169     3,656   1,047   4,703  
Skyrizi —   —   —     42   6   48     76   15   91     193     23   216     311   44   355     266   34   300  
Rinvoq —   —   —     —   —   —     14   —   14     33     —   33     47   —   47     82   4   86  
                                                                                     
Hematologic Oncology 934   239   1,173     1,003   265   1,268     1,184   294   1,478     1,230     317   1,547     4,351   1,115   5,466     1,167   382   1,549  
Imbruvicaa 829   193   1,022     886   213   1,099     1,042   215   1,257     1,073     223   1,296     3,830   844   4,674     966   266   1,232  
Venclexta 105   46   151     117   52   169     142   79   221     157     94   251     521   271   792     201   116   317  
                                                                                     
Aesthetics —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Botox Cosmetic* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Juvederm Collection* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Other Aesthetics* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
                                                                                     
Neuroscience 22   89   111     24   91   115     26   91   117     25     93   118     97   364   461     25   99   124  
Botox Therapeutic* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Vraylar* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Duodopa 22   89   111     24   91   115     26   91   117     25     93   118     97   364   461     25   99   124  
Ubrelvy* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Other Neuroscience* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
                                                                                     
Eye Care —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Lumigan/Ganfort* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Alphagan/Combigan* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Restasis* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Other Eye Care* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
                                                                                     
Women's Health 13   —   13     18   1   19     27   —   27     33     1   34     91   2   93     30   1   31  
Lo Loestrin* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Orilissa 13   —   13     18   1   19     27   —   27     33     1   34     91   2   93     30   1   31  
Other Women's Health* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
                                                                                     
Other Key Products 1,003   425   1,428     1,024   425   1,449     1,017   370   1,387     976     367   1,343     4,020   1,587   5,607     910   363   1,273  
Mavyret 403   387   790     396   384   780     368   327   695     306     322   628     1,473   1,420   2,893     234   325   559  
Creon 227   —   227     257   —   257     265   —   265     292     —   292     1,041   —   1,041     276   —   276  
Lupron 191   38   229     168   41   209     187   43   230     174     45   219     720   167   887     195   38   233  
Linzess/Constella* —   —   —     —   —   —     —   —   —     —     —   —     —   —   —     —   —   —  
Synthroid 182   —   182     203   —   203     197   —   197     204     —   204     786   —   786     205   —   205  

 

a Reflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

 

 

 

AbbVie Inc.

Key Product Revenues

Quarterly Comparable Historical Trend Analysisa, b

(Unaudited, in millions)

 

  1Q19     2Q19     3Q19     4Q19     FY19     1Q20  
  U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total     U.S.   Int’l.   Total  
NET REVENUES $ 8,031   $ 3,359   $ 11,390     $ 9,130   $ 3,137   $ 12,267     $ 9,334   $ 3,069   $ 12,403     $ 9,751   $ 3,192   $ 12,943     $ 36,246   $ 12,757   $ 49,003     $ 9,018   $ 3,151   $ 12,169  
                                                                                   
Immunology 3,215   1,231   4,446     3,835   1,083   4,918     3,977   1,064   5,041     4,195   971   5,166     15,222   4,349   19,571     4,004   1,085   5,089  
Humira 3,215   1,231   4,446     3,793   1,077   4,870     3,887   1,049   4,936     3,969   948   4,917     14,864   4,305   19,169     3,656   1,047   4,703  
Skyrizi —   —   —     42   6   48     76   15   91     193   23   216     311   44   355     266   34   300  
Rinvoq —   —   —     —   —   —     14   —   14     33   —   33     47   —   47     82   4   86  
                                                                         
Hematologic Oncology 934   239   1,173     1,003   265   1,268     1,184   294   1,478     1,230   317   1,547     4,351   1,115   5,466     1,167   382   1,549  
Imbruvicac 829   193   1,022     886   213   1,099     1,042   215   1,257     1,073   223   1,296     3,830   844   4,674     966   266   1,232  
Venclexta 105   46   151     117   52   169     142   79   221     157   94   251     521   271   792     201   116   317  
                                                                         
Aesthetics 648   353   1,001     737   357   1,094     646   358   1,004     742   413   1,155     2,773   1,481   4,254     587   250   837  
Botox Cosmetic* 230   147   377     252   176   428     238   166   404     272   183   455     992   672   1,664     213   114   327  
Juvederm Collection* 129   158   287     157   173   330     135   144   279     167   181   348     588   656   1,244     108   113   221  
Other Aesthetics* 289   48   337     328   8   336     273   48   321     303   49   352     1,193   153   1,346     266   23   289  
                                                                         
Neuroscience 780   185   965     903   192   1,095     923   189   1,112     1,005   198   1,203     3,611   764   4,375     919   192   1,111  
Botox Therapeutic* 403   94   497     454   99   553     439   93   532     469   103   572     1,765   389   2,154     402   89   491  
Vraylar* 148   —   148     201   —   201     241   —   241     291   —   291     881   —   881     285   —   285  
Duodopa 22   89   111     24   91   115     26   91   117     25   93   118     97   364   461     25   99   124  
Ubrelvy* —   —   —     —   —   —     —   —   —     —   —   —     —   —   —     13   —   13  
Other Neuroscience* 207   2   209     224   2   226     217   5   222     220   2   222     868   11   879     194   4   198  
                                                                         
Eye Care 505   292   797     594   327   921     577   313   890     610   319   929     2,286   1,251   3,537     607   283   890  
Lumigan/Ganfort* 70   85   155     69   91   160     69   89   158     79   96   175     287   361   648     81   81   162  
Alphagan/Combigan* 91   38   129     98   41   139     94   40   134     95   43   138     378   162   540     92   37   129  
Restasis* 248   10   258     315   12   327     300   10   310     331   18   349     1,194   50   1,244     314   11   325  
Other Eye Care* 96   159   255     112   183   295     114   174   288     105   162   267     427   678   1,105     120   154   274  
                                                                         
Women's Health 230   8   238     262   10   272     280   11   291     285   13   298     1,057   42   1,099     219   9   228  
Lo Loestrin* 129   3   132     150   3   153     167   3   170     161   5   166     607   14   621     114   3   117  
Orilissa 13   —   13     18   1   19     27   —   27     33   1   34     91   2   93     30   1   31  
Other Women's Health* 88   5   93     94   6   100     86   8   94     91   7   98     359   26   385     75   5   80  
                                                                         
Other Key Products 1,181   430   1,611     1,231   430   1,661     1,237   377   1,614     1,216   374   1,590     4,865   1,611   6,476     1,103   370   1,473  
Mavyret 403   387   790     396   384   780     368   327   695     306   322   628     1,473   1,420   2,893     234   325   559  
Creon 227   —   227     257   —   257     265   —   265     292   —   292     1,041   —   1,041     276   —   276  
Lupron 191   38   229     168   41   209     187   43   230     174   45   219     720   167   887     195   38   233  
Linzess/Constella* 178   5   183     207   5   212     220   7   227     240   7   247     845   24   869     193   7   200  
Synthroid 182   —   182     203   —   203     197   —   197     204   —   204     786   —   786     205   —   205  

  

a Comparable historical net revenues include total revenues for all reported periods for both AbbVie and Allergan products as if the acquisition had closed on January 1, 2019.

b All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

c Reflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

 

 

 EX-101.SCH 3 abbv-20200729.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abbv-20200729_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 abbv-20200729_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] NEW YORK STOCK EXCHANGE, INC. [Member] CHICAGO STOCK EXCHANGE, INC [Member] Sec 1.375 Senior Notes Due 2024 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 2.125 Senior Notes Due 2028 [Member] Sec 1.250 Senior Notes Due 2031 [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Sec 1.375 Senior Notes Due 2024 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 2.125 Senior Notes Due 2028 [Member] Sec 1.250 Senior Notes Due 2031 [Member] EX-101.PRE 6 abbv-20200729_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 tm2025879d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001551152 2020-07-29 2020-07-29 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-07-29 2020-07-29 0001551152 us-gaap:CommonStockMember exch:XCHI 2020-07-29 2020-07-29 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec2.125SeniorNotesDue2028Member exch:XNYS 2020-07-29 2020-07-29 0001551152 abbv:Sec1.250SeniorNotesDue2031Member exch:XNYS 2020-07-29 2020-07-29 iso4217:USD shares iso4217:USD shares 0001551152 false Common Stock, $0.01 Par Value ABBV 8-K 2020-07-29 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value ABBV NYSE CHX 1.375% Senior Notes due 2024 ABBV24 NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Jul. 29, 2020
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 29, 2020
Entity File Number 001-35565
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Entity Tax Identification Number 32-0375147
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name CHX
Sec 1.375 Senior Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Sec 0.750 Senior Notes Due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Sec 2.125 Senior Notes Due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Sec 1.250 Senior Notes Due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 7 95 1 false 7 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbvie.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2025879d1_8k.htm abbv-20200729.xsd abbv-20200729_def.xml abbv-20200729_lab.xml abbv-20200729_pre.xml tm2025879d1_ex99-1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/exch/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2025879d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 7, "dts": { "definitionLink": { "local": [ "abbv-20200729_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2025879d1_8k.htm" ] }, "labelLink": { "local": [ "abbv-20200729_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abbv-20200729_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abbv-20200729.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 72, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 4, "memberStandard": 3, "nsprefix": "abbv", "nsuri": "http://abbvie.com/20200729", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2025879d1_8k.htm", "contextRef": "From2020-07-29to2020-07-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbvie.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2025879d1_8k.htm", "contextRef": "From2020-07-29to2020-07-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "abbv_Sec0.750SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]", "label": "Sec 0.750 Senior Notes Due 2027 [Member]" } } }, "localname": "Sec0.750SeniorNotesDue2027Member", "nsuri": "http://abbvie.com/20200729", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec1.250SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.250 Senior Notes Due 2031 [Member]", "label": "Sec 1.250 Senior Notes Due 2031 [Member]" } } }, "localname": "Sec1.250SeniorNotesDue2031Member", "nsuri": "http://abbvie.com/20200729", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec1.375SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]", "label": "Sec 1.375 Senior Notes Due 2024 [Member]" } } }, "localname": "Sec1.375SeniorNotesDue2024Member", "nsuri": "http://abbvie.com/20200729", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec2.125SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 2.125 Senior Notes Due 2028 [Member]", "label": "Sec 2.125 Senior Notes Due 2028 [Member]" } } }, "localname": "Sec2.125SeniorNotesDue2028Member", "nsuri": "http://abbvie.com/20200729", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001104659-20-087827-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-087827-xbrl.zip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end